The National Asthma Council Logo

 

 

Leading the attack against asthma

Search website
Home About the NAC Strategy Managing Asthma Research Emergency
 
Long-Acting Beta2 Agonists:

Their Place in Asthma Management

 
Asthma Management Handbook Asthma Action Plans Spirometry Resources  Other Resources Information Papers Special Topics Professional Development  

Long-Acting Beta2 Agonists: Their Place in Asthma Management

Home
What are Long-acting Beta2 Agonists
Clinical Use of Symptom Controllers
Recent Studies Characterising the Role of Beta2 Agonists
Dosage and Administration of Symptom Controllers
Content created Aug 1998
Page updated 31 Aug 2005

Get Adobe Reader

Get Adobe Flash Player

 

ForwardBackDosage and Administration of Symptom Controllers

Dosages

Salmeterol - Serevent

 

Eformoterol - Foradile

 

Eformoterol - Oxis

Delivery Devices

The delivery device chosen needs to be age appropriate and match the needs of the patient.

Dry powder inhalers

Limitation of inspiratory flow may decrease drug delivery and clinical response. They are generally not suitable for children under 5-7 years, although some younger children can use them.

Spacer devices

Spacer devices should be used with metered dose inhalers in the following instances:

by all adult patients who have poor co-ordination when using an MDI. by children of all ages.